Anlotinib + Epirubicin (neoadjuvant)
NAET4-SNACC
Eye and ENT Hospital of Fudan University · Phase 2 · Recruiting · Enrollment 76
| Arm | Reported safety |
|---|
A count stays a count. This page does not turn a count into a percent.
ACC
Programs, trials, and reported response and survival for adenoid cystic carcinoma.
Anlotinib + Epirubicin (neoadjuvant)
Eye and ENT Hospital of Fudan University · Phase 2 · Recruiting · Enrollment 76
| Arm | Reported safety |
|---|
A count stays a count. This page does not turn a count into a percent.